Genenta Science, a developer of immuno-oncology and cell-based therapeutics, has strengthened its partnership with AGC Biologics, a global CDMO, by amending their Development and Master Services Agreement. This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta’s cell therapy product, to help ensure compliance with cGMP standards. This strategic move enhances Genenta’s production capabilities, potentially improving efficiency and reliability in its manufacturing processes.

The newly approved methastatic Renal Cell Cancer (mRCC) Phase 1/2a trial began in 4Q24, and Genenta expects to treat six patients by the end of 1H25, while continuing progress with the Glioblastoma Multimforme (GBM) study. In total, Genenta projects manufacturing 27 autologous drug products in 2025.

“Our strengthened partnership with AGC Biologics represents our unwavering commitment to patients participating in our GBM and mRCC trials,” said Pierluigi Paracchi, CEO and Co-founder of Genenta. “This enhanced capacity ensures that we can treat a larger number of patients and further validate our therapeutic approach, bringing us closer to our vision of transforming cancer treatment through cell-based therapies.”